1. Home
  2. PCRX vs AUTL Comparison

PCRX vs AUTL Comparison

Compare PCRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$24.70

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Autolus Therapeutics plc

AUTL

Autolus Therapeutics plc

HOLD

Current Price

$2.00

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
AUTL
Founded
2006
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
596.2M
IPO Year
2010
2025

Fundamental Metrics

Financial Performance
Metric
PCRX
AUTL
Price
$24.70
$2.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$30.25
$8.50
AVG Volume (30 Days)
429.3K
1.4M
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
107.44
N/A
EPS
0.19
N/A
Revenue
$541,533,000.00
$10,120,000.00
Revenue This Year
$6.78
$80.32
Revenue Next Year
$8.54
$53.96
P/E Ratio
$130.00
N/A
Revenue Growth
26.04
496.00
52 Week Low
$18.80
$1.18
52 Week High
$27.66
$2.58

Technical Indicators

Market Signals
Indicator
PCRX
AUTL
Relative Strength Index (RSI) 49.49 49.07
Support Level $24.61 $1.37
Resistance Level $25.17 $2.07
Average True Range (ATR) 0.74 0.09
MACD -0.10 -0.03
Stochastic Oscillator 42.32 36.11

Price Performance

Historical Comparison
PCRX
AUTL

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About AUTL Autolus Therapeutics plc

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.

Share on Social Networks: